Westmount Partners LLC Grows Stake in Novo Nordisk A/S (NYSE:NVO)

Westmount Partners LLC lifted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 13.1% in the fourth quarter, Holdings Channel reports. The firm owned 2,405 shares of the company’s stock after buying an additional 279 shares during the period. Westmount Partners LLC’s holdings in Novo Nordisk A/S were worth $207,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. Salem Investment Counselors Inc. grew its stake in Novo Nordisk A/S by 2.3% during the 4th quarter. Salem Investment Counselors Inc. now owns 21,926 shares of the company’s stock valued at $1,886,000 after acquiring an additional 491 shares in the last quarter. Thomasville National Bank grew its stake in Novo Nordisk A/S by 54.0% during the 4th quarter. Thomasville National Bank now owns 2,933 shares of the company’s stock valued at $252,000 after acquiring an additional 1,028 shares in the last quarter. Capital Investment Advisors LLC grew its stake in Novo Nordisk A/S by 12.1% during the 4th quarter. Capital Investment Advisors LLC now owns 4,435 shares of the company’s stock valued at $382,000 after acquiring an additional 478 shares in the last quarter. Fiduciary Alliance LLC grew its stake in Novo Nordisk A/S by 11.4% during the 4th quarter. Fiduciary Alliance LLC now owns 8,107 shares of the company’s stock valued at $697,000 after acquiring an additional 829 shares in the last quarter. Finally, Atlas Brown Inc. grew its stake in Novo Nordisk A/S by 33.4% during the 4th quarter. Atlas Brown Inc. now owns 5,130 shares of the company’s stock valued at $441,000 after acquiring an additional 1,285 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analysts Set New Price Targets

NVO has been the subject of several research reports. BMO Capital Markets dropped their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Finally, Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $140.20.

Novo Nordisk A/S Stock Down 2.2 %

Novo Nordisk A/S stock traded down $1.90 during mid-day trading on Monday, reaching $84.36. 5,034,926 shares of the company’s stock were exchanged, compared to its average volume of 7,056,390. The company has a market cap of $378.57 billion, a P/E ratio of 27.30, a P/E/G ratio of 1.37 and a beta of 0.45. Novo Nordisk A/S has a twelve month low of $81.50 and a twelve month high of $148.15. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The company has a fifty day moving average of $100.35 and a 200-day moving average of $119.04.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.